Mentshlichkeit* (8.7.2026)
Dr. Jack Cush reviews the news and recent journal reports on RheumNow.com.
Read Article
Retrospective study, 41 pediatric Behcets Dz pts looked at Inflam. indices (NLR, SII, PIV, CRP/albumin) vs controls. BD systemic involvement in 68%, CNS dz in 10%, Vascular Dz in 12% & major organ dz 46%. Inflamm indices significantly higher in BD w/ systemic, CNS, & Vasc https://t.co/wHiBIaOWWU
Dr. John Cush @RheumNow( View Tweet )
A Tribute to Daniel L. Kastner, MD, PhD (1951–2026)
The rheumatology, genetics and NIH communities mourn for Dr. Daniel L. Kastner, who died on July 28, 2026, in Bethesda, Maryland, at age 74. The following are declarations, tributes, and memories dedicated to this mensch of a man, titan of science, memorable mentor and humble physician.
Read Article
$2 Million in Research Grants for Juvenile Arthritis
July is Juvenile Arthritis Awareness Month, and while many people think of arthritis as a disease of aging, nearly 300,000 children in the U.S. are living with a rheumatic disease.
Equally important is that 2026 marks a 50 year anniversary for Pediatric
Read Article
Chinese cohort of 209 AOSD pts identifed 49 (23%) w/ lung dz (by CXR), yet 69% were asymptomatic. Significcant risk factors for AOSD-LD were pleuritis, MAS (HR 2.62), & Dz relapse (HR 2.6). Imaging patterns: acute exudative pattern most prevalent, followed by interstitial and https://t.co/2IPJWRJicP
Dr. John Cush @RheumNow( View Tweet )
Chikungunya Club Meeting (7.24.2026)
Dr. Jack Cush reviews the news, journal reports from the past week on RheumNow.com.
Read Article
51 yoM w/ 2 yrs of FUO, unintentional 32-kg wt loss, LN, diffuse myalgias, but no GI Sxs or arthralgia. Neg MRIs, CT, PET scan, EGD, colonoscopy. Abnl labs: CRP 173 mg/L, ESR 46, anemia & ^ WBC. Cell-free DNA next-generation sequencing dx Tropheryma whipplei, & Whipple disease https://t.co/nJLa4l7Ers
Dr. John Cush @RheumNow( View Tweet )
2 Still's dz cohorts (96 Shanghai, 28 Erlangen0 compared response to biolgics vs DMARDs (MTX, CNI,JAKi). in 124 AOSD pts, biologic had more sustained event-free remission and event-free state (P 0.0065, P 0.0096) & more steroid D/C vs MTX/CNI (p < 0.05). https://t.co/lJaI9nhPYr
Dr. John Cush @RheumNow( View Tweet )
Gout Cavalcade (7.10.2026)
Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week. July is Gout: More than Flares month.
Read Article
ICYMI: VEXAS Syndrome - A Review
Beck et al has published a review of the VEXAS syndrome in The Lancet, focusing on the pathogenesis, spectrum, and treatment strategies.
https://t.co/K9IMLBdCGI https://t.co/LJdnRflzsU
Dr. John Cush @RheumNow( View Tweet )
From Cytokine Endotypes to Clinical Reality in Still’s Disease
Recent EULAR 2026 data highlight a paradigm shift in Still’s disease from syndromic management to biologically informed precision therapy.
https://t.co/fBtkDLPJNE https://t.co/y8NBW6VHHa
Dr. John Cush @RheumNow( View Tweet )
From Cytokine Endotypes to Clinical Reality in Still’s Disease
Recent EULAR 2026 data highlight a paradigm shift in Still’s disease from syndromic management to biologically informed precision therapy.
https://t.co/FrghBJdlXj https://t.co/CbHYDKbnK9
Dr. John Cush @RheumNow( View Tweet )
From Cytokine Endotypes to Clinical Reality in Still’s Disease
Recent EULAR 2026 data highlight a paradigm shift in Still’s disease from syndromic management to biologically informed precision therapy.
Read Article
What’s New in Macrophage Activation Syndrome Therapeutics
MAS, the most severe complication of Still’s disease, is increasingly recognized as a cytokine-driven hyperinflammatory state centered on interferon gamma (IFNγ). Therapeutic advances presented at EULAR 2026 demonstrate both consolidation of established pathways and expansion into novel biologic
Read Article
Emapalumab in MAS secondary to stills disease
39 pts, median age 12, 2 pooled prospective, open label, single arm studies.
Endpoint complete resolution at week 8-. Around 60% and partial resolution nearly 100%
67% had concomitant anakinra
@RheumNow ##EULAR2026 #EULARBest https://t.co/sGm43C3LfH
Links:
Bella Mehta @bella_mehta( View Tweet )
Window of opportunity in stills disease is early. With IL1 / IL6 agents
#sJIA and #AOSD are the same disease. - may need a standard new crieteria
IL18 measuremnet should be encouraged.
@RheumNow #EULAR2026 plenary https://t.co/EQbs9mDYjS
Links:
Bella Mehta @bella_mehta( View Tweet )
Transitioning from pediatrics to adult rheumatology for patients with autoinflammatory disease such as #AOSD should be done with administrative support and the right hand off.
@RheumNow #EULAR2026 plenary talk https://t.co/N8qB7jrZfM
Links:
Bella Mehta @bella_mehta( View Tweet )
Sad to see this but important to be aware. Increasing risk of suicide using colchicine in Familial Mediterranean Fever. #POS0768 #EULAR2026 @rheumnow.
Average age 28! 87%female, only 7 % with psychiatric referral!
Retrospective 15 pts. https://t.co/241SE6O395
Links:
Bella Mehta @bella_mehta( View Tweet )
#EULAR2026 OP028 In 16 patients with AID (SSc,IIM, RA, IgG4,SjD, Grave’s), CD3xBCMA BiTE, Teclistamab was effective in 15/16. Duration of GC & DMARD-free was 11 mths. 2/16 need retreatment. All had low IgG and needed IVIG. Need long-term safety data & comparative study @RheumNow https://t.co/97MUPnXRua
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Multisystem inflammatory syndrome in children (MIS-C) - analysis of cases 2023-2024 shows 99% were undervaccinated against COVID-19. OVer 2 yrs, 141 MIS-C 78%had no COVID-19 vaccine. All 4 children who died were unvaccinated https://t.co/iBcA4GIdDe https://t.co/IQLLaG55gm
Dr. John Cush @RheumNow( View Tweet )
Review of Ruxolitinib in 7 pts w/ refractory systemic JIA complicated by macrophage activation (MAS) (ages 1.6-11 yrs; 3M: 4F). 5 achieved complete remission; 2 partial remission. 2 relapsed w/ GC tapering (remission after adding canakinumab). No deaths https://t.co/j4Cm3UYB9c https://t.co/pKoDwpSKII
Dr. John Cush @RheumNow( View Tweet )
Review of Ruxolitinib in 7 pts w/ refractory systemic JIA complicated by macrophage activation (MAS) (ages 1.6-11 yrs; 3M: 4F). 5 achieved complete remission; 2 partial remission. 2 relapsed w/ GC tapering (remission after adding canakinumab). No deaths https://t.co/j4Cm3UYB9c https://t.co/YIupsBank5
Dr. John Cush @RheumNow( View Tweet )
Quiz Talk (5.22.2026)
Dr. Jack Cush talks of birthdays, Quizzes and journal articles this week on the podcast.
Read Article
FDA has approved benralizumab (Fasenra) for the treatment of adult and pediatric patients w/ hypereosinophilic syndrome (HES); based on the NATRON Phase III trial https://t.co/qqPsjhUClP https://t.co/lCZNoTh9fv
Dr. John Cush @RheumNow( View Tweet )
10yr retrosp. study of 110 Still’s dz pts. MAS occurred in 37% (1/2 @onset; assoc w/ serositis) and ILD observed in 82% (also assoc w/ MAS, polycyclic course) https://t.co/SNa0KiWfgY https://t.co/xbpCuHdJka
Dr. John Cush @RheumNow( View Tweet )
Therapeutic Updates
Dr. Jack Cush reviews the history, manifestations, diagnosis and treatment of Still's disease.
Read Post
Recent Blogs
Dr. Cush provides a systematic approach to evaluating musculoskeletal and rheumatic complaints in clinical practice.
Read Article
Adult-onset Still's presents an interesting and diagnostic challenge when encountered. Here are 5 tips to improve your diagnostic acumen for this febrile disorder.
Read Post
Podcasts
ACR 2025 Daily Podcasts Day2d
AOSD - Adult - Onset Still's Disease00:33:08 
ACR Fireside Chats - Still's disease Abstracts00:22:48
